Compare Funko Inc (FNKO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Funko Inc trades at $6.31 (market cap $355.57M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 14.1× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FNKO | TVTX | |
|---|---|---|
Market Cap | $355.57M | $5.02B |
Volume | 738,460 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $67.52 |
52-Week Low | $2.81 | $26.79 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $576.22M | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.52, up 0.93% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% to $207.7M, and raised EBITDA guidance to $105M. Despite negative net margins, the stock trades at attractive valuations with P/S of 0.39x and EV/EBITDA of 6.84x. Recent management changes and product expansions signal strategic momentum.
FNKO presents a turnaround opportunity with improving operational metrics and positive analyst sentiment, though risks remain from inconsistent profitability and high debt levels. The consensus price target of $7.58 suggests 16% upside potential, supported by strong Q2 results and raised guidance. Investors should weigh the company's progress against ongoing margin pressures and competitive challenges in the collectibles market.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
